Phase 3 study of Trodelvy for advanced lung cancer misses primary endpoint

A randomized phase 3 study designed to assess sacituzumab govitecan-hziy for treatment of previously treated metastatic non-small cell lung cancer failed to meet its primary endpoint of OS, according to the agent’s manufacturer.
Sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences) is a Trop-2-directed antibody-drug conjugate. The agent is approved for treatment of certain patients with breast cancer or urothelial cancer.
The EVOKE-01 study included 603 patients with metastatic or advanced NSCLC that progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart